Skip to content
Clinical Trials – home
Not yet recruiting

Safety and Efficacy of Ceftobiprole Medocaril Sodium in Children with Staphylococcus aureus Bacteremia Including Right‑Sided Infective Endocarditis

Verified siteRegistered drugNo placebo
Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

What is this trial about?

A plain-language summary of the goals, design and what participants do

The study looks at children from birth to less than 18 years who have a bloodstream infection called Staphylococcus aureus bacteremia. This infection can sometimes spread to the heart valves, causing right-sided infective endocarditis. The trial compares a new antibiotic, ceftobiprole, given as a drip, with the usual medicines doctors normally use, called the standard-of-care. The main purpose is to find out if the new drug is safe for children and works as well as the usual treatment. “Pharmacokinetics” means how the drug moves through the body, including how it is absorbed, spread, broken down, and removed.

Children who meet the study rules are randomly assigned to receive either the new drug or the usual treatment, and neither the doctors who decide care nor the staff who record results know which child got which medicine. The medication is given by an intravenous infusion for a set number of days, after which the children are checked at several visits to see how they feel, if any side effects occurred, and whether the infection cleared. Follow‑up continues for about a month after the last dose to monitor safety and overall recovery.

The research process

The trial runs in 9 steps – from screening to follow-up. Each step says what happens and what the team monitors.

  1. Step 1

    Enrollment and Consent

    After you agree to participate, you sign an informed consent form. This confirms that you understand the purpose of the study and the procedures involved.

  2. Step 2

    Screening Assessments

    Study staff collect your medical history, perform a physical examination, and take blood samples to confirm the presence of Staphylococcus aureus bacteremia (infection of the bloodstream).

    Additional laboratory tests are done to evaluate kidney function, liver function, and other safety parameters before any medication is given.

  3. Step 3

    Randomization

    You are randomly assigned to receive either ceftobiprole or the standard of care treatment. Randomization ensures that the assignment is not influenced by any personal characteristics.

  4. Step 4

    Start of Treatment

    If you are assigned to the investigational group, you receive ceftobiprole 500 mg as a intravenous infusion. The medication is delivered through a vein using a syringe pump or infusion set, according to the study schedule.

    If you are assigned to the control group, you receive the standard antibiotic therapy that is normally used for this infection. The exact dose and frequency are determined by the treating physician based on current medical practice.

  5. Step 5

    Daily Monitoring During Treatment

    Each day you have your vital signs (temperature, heart rate, blood pressure) measured and blood drawn for safety laboratory tests.

    Study staff ask you about any new or worsening symptoms, such as pain, fever, or rash, and record any adverse events (unwanted medical occurrences). Specific terms include:

    TEAEs – treatment‑emergent adverse events, which are side effects that appear after the study drug is started;

    SAEs – serious adverse events, which are medical problems that require hospitalization or are life‑threatening;

    AESIs – adverse events of special interest, which are side effects the investigators are particularly watching for.

  6. Step 6

    Evaluation of Infection Response

    Doctors assess whether the infection is improving by checking clinical signs such as fever and heart rhythm, and by reviewing repeat blood cultures.

    A successful outcome is called clinical success (cure or improvement) and microbiological response (eradication of the bacteria from the bloodstream).

  7. Step 7

    End of Treatment

    When the prescribed course of medication is completed, the study treatment stops. The exact number of days of therapy is determined by the investigator based on the severity of the infection and your response.

  8. Step 8

    Follow‑Up Visit (TOC)

    Approximately 28 days after the end of treatment, you return for a follow‑up visit, often called the TOC (test‑of‑cure) visit.

    During this visit, the investigator records any late‑appearing adverse events, checks for new complications such as metastatic infection sites, and confirms whether you have achieved overall success (both clinical and microbiological).

  9. Step 9

    Final Safety Assessment

    At the conclusion of the study, all safety data—including laboratory results, vital signs, and reported adverse events—are reviewed to determine the overall safety profile of ceftobiprole compared with the standard treatment.

Who can join the trial?

5 criteria

  • Pediatric patients from birth up to less than 18 years old, weighing at least 3.7 kg. Babies younger than 2 years must have been born at 37 weeks or later (full‑term) and be at least 3 days old after birth.
  • A parent or legal guardian must give written permission (called informed consent) and be able to follow all study steps; the child must also agree (called assent) if they are old enough to understand.
  • The child must have a confirmed infection called Staphylococcus aureus bacteremia (SAB). This is proven by a positive blood culture (a lab test that grows bacteria from a blood sample) taken within 48 hours before joining the study, or by a persistent positive blood culture taken within 72 hours after at least 4 days of appropriate antibiotics.
  • The child must have a good vein (adequate venous access) so that blood samples can be taken and the study medication can be given.
  • If the child could become pregnant, they must use an acceptable method of birth control from at least 30 days before the screening visit until at least 28 days after the last dose of the study drug.

Who cannot join the trial?

21 criteria

  • You cannot join if you have already taken antibiotics that treat the whole body (systemic antibacterial treatment) for a Staphylococcus aureus infection for more than two days in the week before the study, unless the infection has not cleared after at least four days of appropriate treatment or the bacteria is resistant (not killed) by those antibiotics.
  • You cannot join if the Staphylococcus aureus bacteria causing your infection is known or suspected to be non‑susceptible (unlikely to be killed) by ceftobiprole or the standard antibiotics used for comparison.
  • You cannot join if you have another infection at the time of screening caused by Gram‑negative bacteria (a different group of bacteria).
  • You cannot join if you have an infection of the inner lining of the left side of the heart (left‑sided infective endocarditis, or IE).
  • You cannot join if you have a contraindication (a medical reason you cannot receive the study drugs), including a known allergy (hypersensitivity) to beta‑lactam antibiotics (the class of drugs used in the study).
  • You cannot join if you have taken part in another clinical trial with an experimental drug or device within the past 30 days (or longer, depending on the drug’s half‑life), or if you have previously participated in this study.
  • You cannot join if doctors consider that you have a high chance of dying within 7 days from this infection or within 28 days from another serious illness.
  • You cannot join if a blood test shows a very low count of neutrophils (a type of white blood cell that fights infection), specifically an absolute neutrophil count less than 0.5 × 10⁹/L.
  • You cannot join if you are in septic shock (a severe infection causing dangerously low blood pressure) or have low blood pressure that does not improve after at least four hours of IV fluids and medicines that raise blood pressure (vasopressors).
  • You cannot join if you have Staphylococcus aureus bacteremia (SAB) and also have implanted medical devices (foreign body material) that cannot be removed within 7 days after randomization, unless those devices are not infected and meet specific timing rules (e.g., certain catheters, stents, prosthetic joints, plates, spinal hardware, or filters placed long enough ago).
  • You cannot join if the infection is suspected or confirmed to have spread to the brain or spinal cord (metastatic central nervous system infection).
  • You cannot join if you have an immunocompromising condition, such as HIV/AIDS with low CD4 cell counts (less than 750 cells/mm³ for infants, 500 for children 1‑<6 years, or 200 for children ≥6 years), recent bone‑marrow transplant or ablative therapy, graft‑versus‑host disease, recent organ‑transplant rejection, severe combined immunodeficiency, or similar disorders that weaken the immune system.
  • You cannot join if you have taken high‑dose systemic steroids (prednisolone > 2 mg/kg per day or equivalent) or other immunosuppressive drugs within the two weeks before screening.
  • You cannot join if you have any severe, acute or chronic medical or psychiatric condition, a recent neurological event, or abnormal lab results that could increase risk or affect the study results, as judged by the investigator.
  • You cannot join if you are expected to need anti‑Staphylococcal antibiotics for more than 42 days (about six weeks).
  • You cannot join if you will need other systemic antibiotics that work against Staphylococcus aureus for reasons unrelated to this infection (for example, preventive antibiotics before planned surgery or acne medication) during the study period.
  • You cannot join if your kidney function is very low, measured by an estimated glomerular filtration rate (eGFR) below 30 mL/min/1.73 m² for children under 2 years old or below 15 mL/min/1.73 m² for children 2 years and older, or if you require dialysis or similar kidney‑replacement therapies.
  • You cannot join if you have a history of seizures, except for well‑documented fever‑related seizures (febrile seizures) that occur in early childhood.
  • You cannot join if your liver blood tests are markedly abnormal: alanine transaminase (ALT) or aspartate transaminase (AST) more than five times the normal upper limit, total bilirubin more than twice normal (unless it is a benign condition called Gilbert’s syndrome), or you have severe liver disease classified as Child‑Pugh class C.
  • You cannot join if you are pregnant or breastfeeding.
  • You cannot join if you have used illegal drugs (such as heroin, non‑prescribed opioids, cocaine, crack cocaine, amphetamines, or methamphetamine) within the past 12 months.
Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.

We usually reply within a few days

Verified sites

All sites with verified contact details – recruitment status may not be available; ask directly

Trial locations

Where you can join this trial

Countries are shaded by recruitment status. Click a recruiting country to ask about joining there.

Not yet recruiting
Not finding your country?

Not sure what to do next?

Joining a clinical trial can seem overwhelming. We guide you step by step, so you know exactly what to expect and how we support you through the process.

See the full process and FAQ

Investigated drugs

  • ceftobiprole

    is an antibiotic that is given through a vein (intravenous infusion). It is used to treat infections caused by the bacteria Staphylococcus aureus, including serious blood infections (bacteremia) and infections of the heart lining (right‑sided infective endocarditis). In this study, the medicine is being tested to see how safe it is for children from birth up to 18 years old, and how well it works compared with the usual treatments.

  • Standard‑of‑care treatment

    refers to the usual antibiotics and medical care that doctors normally give to children with Staphylococcus aureus bacteremia and related infections. These treatments are the current best practice and are used as a comparison to see if the new medication, ceftobiprole, offers any advantages in safety or effectiveness.

What is already known about the treatment

Zevtera 500 mg powder for concentrate for solution for infusion - It is given by intravenous infusion, where the powder is mixed with fluid and delivered into a vein. Ceftobiprole medocaril sodium is an approved antibiotic in several countries and has been studied in many clinical papers for treating serious bacterial infections. It is mainly used to treat bloodstream infections caused by Staphylococcus aureus, including right‑sided infective endocarditis. The drug works by attaching to proteins that build the bacterial cell wall, stopping the wall from forming and causing the bacteria to die; it belongs to the cephalosporin class of antibiotics.

Investigated diseases

Staphylococcus aureus bacteremia, including right-sided infective endocarditis - This condition is a bloodstream infection caused by the bacterium Staphylococcus aureus. The bacteria enter the blood and can travel to different parts of the body. When they reach the right side of the heart, they may attach to the heart valves and form an infection called right‑sided infective endocarditis. The infection can produce small growths on the valves that may break off and travel to other organs. As the bacteria spread, new sites of infection can develop, leading to additional symptoms. The disease typically evolves from an initial fever and chills to more localized problems as the infection spreads.
Trial detailsLast updated 20 Nov 2026
Age0-17PhasePhase IIITrial ID2025-524965-25-00Protocol codeCSBAL5788-2025-002Estimated enrolment60 patientsSponsorIstx LLC

sourced from the EU Clinical Trials Register and site verification

Want to learn more about this trial or check if you can participate?

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.